Literature DB >> 21425146

MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck.

Scott M Langevin1, Roslyn A Stone, Clareann H Bunker, Maureen A Lyons-Weiler, William A LaFramboise, Lori Kelly, Raja R Seethala, Jennifer R Grandis, Robert W Sobol, Emanuela Taioli.   

Abstract

BACKGROUND: The overall 5-year survival rate of approximately 60% for head and neck cancer patients has remained essentially unchanged over the past 30 years. MicroRNA-137 (miR-137) plays an essential role in cell-cycle control at the G1/S-phase checkpoint. However, the aberrant miR-137 promoter methylation observed in squamous cell carcinoma of the head and neck (SCCHN) suggests a tumor-specific molecular defect that may contribute to disease progression.
METHODS: The goal of this study was to assess, in formalin-fixed, paraffin-embedded tumor tissue, the association between miR-137 promoter methylation and survival (both overall and disease free) and with prognostic factors including stage, tumor size, lymph node positivity, tumor grade, and surgical tumor margin positivity.
RESULTS: The promoter methylation status of miR-137 was ascertained by methylation-specific polymerase chain reaction and detected in 11 of 67 SCCHN patients (16.4%), with no significant differences according to site (oral cavity, pharynx, larynx). Methylation of the miR-137 promoter was significantly associated with overall survival (hazard ratio, 3.68; 95% confidence interval, 1.01-13.38) but not with disease-free survival or any of the prognostic factors evaluated.
CONCLUSIONS: The results of this study indicate that miR-137 is methylated in tumor tissue from pharyngeal and laryngeal squamous cancers, in addition to oral squamous cell carcinoma, and that miR-137 promoter methylation has potential utility as a prognostic marker for SCCHN.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21425146      PMCID: PMC3117118          DOI: 10.1002/cncr.25689

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  53 in total

1.  Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma.

Authors:  K-W Chang; C-J Liu; T-H Chu; H-W Cheng; P-S Hung; W-Y Hu; S-C Lin
Journal:  J Dent Res       Date:  2008-11       Impact factor: 6.116

2.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.

Authors:  Li-Xu Yan; Xiu-Fang Huang; Qiong Shao; Ma-Yan Huang; Ling Deng; Qiu-Liang Wu; Yi-Xin Zeng; Jian-Yong Shao
Journal:  RNA       Date:  2008-09-23       Impact factor: 4.942

3.  Methylation-specific PCR.

Authors:  Julien D F Licchesi; James G Herman
Journal:  Methods Mol Biol       Date:  2009

4.  Diagnostic and prognostic microRNAs in stage II colon cancer.

Authors:  Troels Schepeler; Jørgen T Reinert; Marie S Ostenfeld; Lise L Christensen; Asli N Silahtaroglu; Lars Dyrskjøt; Carsten Wiuf; Frank J Sørensen; Mogens Kruhøffer; Søren Laurberg; Sakari Kauppinen; Torben F Ørntoft; Claus L Andersen
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

5.  Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype.

Authors:  Erin Connolly; Margherita Melegari; Pablo Landgraf; Tatyana Tchaikovskaya; Bud C Tennant; Betty L Slagle; Leslie E Rogler; Mihaela Zavolan; Thomas Tuschl; Charles E Rogler
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

6.  MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.

Authors:  Jian-Jun Zhao; Jianhong Lin; Hua Yang; William Kong; Lili He; Xu Ma; Domenico Coppola; Jin Q Cheng
Journal:  J Biol Chem       Date:  2008-09-12       Impact factor: 5.157

7.  Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma.

Authors:  Jessica Pierson; Bruce Hostager; Rong Fan; Rajeev Vibhakar
Journal:  J Neurooncol       Date:  2008-07-08       Impact factor: 4.130

8.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Authors:  Dmitri Lodygin; Valery Tarasov; Alexey Epanchintsev; Carola Berking; Tatjana Knyazeva; Henrike Körner; Piotr Knyazev; Joachim Diebold; Heiko Hermeking
Journal:  Cell Cycle       Date:  2008-08-01       Impact factor: 4.534

9.  Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR.

Authors:  Athina Markou; Emily G Tsaroucha; Loukas Kaklamanis; Marianthi Fotinou; Vassilis Georgoulias; Evi S Lianidou
Journal:  Clin Chem       Date:  2008-08-21       Impact factor: 8.327

10.  miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Authors:  Joachim Silber; Daniel A Lim; Claudia Petritsch; Anders I Persson; Alika K Maunakea; Mamie Yu; Scott R Vandenberg; David G Ginzinger; C David James; Joseph F Costello; Gabriele Bergers; William A Weiss; Arturo Alvarez-Buylla; J Graeme Hodgson
Journal:  BMC Med       Date:  2008-06-24       Impact factor: 8.775

View more
  39 in total

Review 1.  MicroRNAs in brain tumors : a new diagnostic and therapeutic perspective?

Authors:  Richard Hummel; Jessica Maurer; Joerg Haier
Journal:  Mol Neurobiol       Date:  2011-07-08       Impact factor: 5.590

2.  The Roles of Two miRNAs in Regulating the Immune Response of Sea Cucumber.

Authors:  Pengjuan Zhang; Chenghua Li; Ran Zhang; Weiwei Zhang; Chunhua Jin; Lingling Wang; Linsheng Song
Journal:  Genetics       Date:  2015-10-19       Impact factor: 4.562

Review 3.  Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer.

Authors:  Reo Maruyama; Hiromu Suzuki; Eiichiro Yamamoto; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2012-01-05

4.  Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer.

Authors:  Graham M Poage; Rondi A Butler; E Andrés Houseman; Michael D McClean; Heather H Nelson; Brock C Christensen; Carmen J Marsit; Karl T Kelsey
Journal:  Cancer Res       Date:  2012-04-16       Impact factor: 12.701

Review 5.  A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia.

Authors:  Kensuke Sakamoto; James J Crowley
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-06-14       Impact factor: 3.568

6.  Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas.

Authors:  Thomas Harris; Lizandra Jimenez; Nicole Kawachi; Jian-Bing Fan; Jing Chen; Tom Belbin; Andrew Ramnauth; Olivier Loudig; Christian E Keller; Richard Smith; Michael B Prystowsky; Nicolas F Schlecht; Jeffrey E Segall; Geoffrey Childs
Journal:  Am J Pathol       Date:  2012-01-09       Impact factor: 4.307

7.  MicroRNA-137 suppresses tongue squamous carcinoma cell proliferation, migration and invasion.

Authors:  Lanying Sun; Jin Liang; Qibao Wang; Zhaoyuan Li; Yi Du; Xin Xu
Journal:  Cell Prolif       Date:  2016-08-30       Impact factor: 6.831

Review 8.  DNA methylation and microRNA dysregulation in cancer.

Authors:  Hiromu Suzuki; Reo Maruyama; Eiichiro Yamamoto; Masahiro Kai
Journal:  Mol Oncol       Date:  2012-08-10       Impact factor: 6.603

9.  miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells.

Authors:  A A Takwi; Y-M Wang; J Wu; M Michaelis; J Cinatl; T Chen
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

Review 10.  Regulation of DNA methylation machinery by epi-miRNAs in human cancer: emerging new targets in cancer therapy.

Authors:  Mohammad Reza Karimzadeh; Peyman Pourdavoud; Naeim Ehtesham; Mohaddese Qadbeigi; Masood Movahedi Asl; Behrang Alani; Meysam Mosallaei; Bahram Pakzad
Journal:  Cancer Gene Ther       Date:  2020-08-10       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.